Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Viruses 2021-06, Vol.13 (6), p.1151
Hauptverfasser: Minosse, Claudia, Gruber, Cesare E. M., Rueca, Martina, Taibi, Chiara, Zaccarelli, Mauro, Grilli, Elisabetta, Montalbano, Marzia, Capobianchi, Maria R., Antinori, Andrea, D’Offizi, Gianpiero, McPhee, Fiona, Garbuglia, Anna Rosa
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral agents
Automation
DNA polymerase
Genotype & phenotype
HCV
HCV late relapse
HCV reinfection
Hepatitis
Hepatitis C
hepatitis C virus
HIV
Human immunodeficiency virus
Infections
Next-generation sequencing
NGS
Patients
Polymerase chain reaction
Ribonucleic acid
RNA
RNA-directed RNA polymerase
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is
ISSN:1999-4915
1999-4915
DOI:10.3390/v13061151